BW

06
Ene
By MetroLatinoUSA
BW

Akoya Appoints Paul LaRusso as CEO

BOSTON--(BUSINESS WIRE)--Akoya announced today that Paul LaRusso has been named Chief Executive Officer and will remain a member of Akoya’s board of directors, succeeding Stuart Rubinstein in the role who, in early 2022 shared his desire to retire by year end with the board. “On behalf of the board, I…
Leer más...
06
Ene
By MetroLatinoUSA
BW

Principal® announces pension joint venture in China

Expanding global footprint will provide Chinese customers access to retirement solutions DES MOINES, Iowa--(BUSINESS WIRE)--Principal Financial Group®, a leading global financial services provider, today announced an exciting new chapter in their ongoing expansion of their global pension footprint as Principal® acquires a minority ownership stake (17.647%) in China Construction Bank…
Leer más...
06
Ene
By MetroLatinoUSA
BW

Veros Reports That Its National Housing Market Annual Forecast Goes Negative for the First Time in More Than a Decade

SANTA ANA, Calif.--(BUSINESS WIRE)--#homevalues--Today, Veros® Real Estate Solutions, an industry leader in enterprise risk management and collateral valuation services, released its 2022 Q4 VeroFORECASTSM that anticipates home prices will turn negative overall and depreciate on average by -0.5% for the next twelve months. This is a significant drop from the…
Leer más...
06
Ene
By MetroLatinoUSA
BW

FDA Grants Priority Review to Genentech’s Bispecific Antibody Glofitamab for People With Relapsed or Refractory Large B-Cell Lymphoma

– If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type of non-Hodgkin’s lymphoma – – Results from the pivotal Phase I/II NP30179 study showed glofitamab induced durable response rates in people with heavily pretreated large B-cell lymphoma, with 40%…
Leer más...
05
Ene
By MetroLatinoUSA
BW

Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock.…
Leer más...
05
Ene
By MetroLatinoUSA
BW

EMBECTA ALERT: Bragar Eagel & Squire, P.C. is Investigating Embecta Corp. on Behalf of Embecta Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of Embecta stockholders. Our investigation concerns whether Embecta has violated the federal securities laws and/or engaged in other unlawful business practices.…
Leer más...
05
Ene
By MetroLatinoUSA
BW

UP FINTECH ALERT: Bragar Eagel & Squire, P.C. is Investigating UP Fintech Holding Limited on Behalf of UP Fintech Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)--#A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against UP Fintech Holding Limited (“UP Fintech” or the “Company”) (NASDAQ: TIGR) on behalf of UP Fintech stockholders. Our investigation concerns whether UP Fintech has violated the federal securities laws and/or engaged…
Leer más...
¡Síguenos en Facebook!
¡Síguenos en Twitter!